Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial-Reference-Cited by-同舟云学术

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Published:2008-11 Issue:9652 Volume:372 Page:1809-1818
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kim Edward S,Hirsh Vera,Mok Tony,Socinski Mark A,Gervais Radj,Wu Yi-Long,Li Long-Yun,Watkins Claire L,Sellers Mark V,Lowe Elizabeth S,Sun Yan,Liao Mei-Lin,Østerlind Kell,Reck Martin,Armour Alison A,Shepherd Frances A,Lippman Scott M,Douillard Jean-Yves

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

2. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

3. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

4. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens;Fossella;J Clin Oncol,2000

5. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

Cited by 1102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Advancements in precision oncology: Investigating the function of circulating DNA in the advancement of liquid biopsy technologies;The Journal of Liquid Biopsy;2024-09

3. Two-stage Adaptive Enrichment Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers;Statistics in Biopharmaceutical Research;2024-08-29

4. Nephrotoxicity of targeted therapy used to treat lung cancer;Frontiers in Immunology;2024-07-04

5. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment;Microvascular Research;2024-07